BioSpace News Archive

Monotherapy Phase I dose escalation remains ongoing; BT5528 appears well-tolerated as dosing approaches clinically relevant levels

Acceleron Pharma Inc. announced it will host a webcast and conference call on Monday, May 11, 2020 at 5:00 p.m. EDT to discuss its first quarter 2020 operating and financial results.

Total product and royalty revenues of $569 million (+24% vs Q1 2019) for the quarter ended March 31, 2020; Jakafi® (ruxolitinib) revenues of $459 million in Q1 2020 (+22% vs Q1 2019)

Exicure, Inc., the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid constructs, will present at the American Association of Cancer Research Virtual Annual Meeting II, occurring June 22 – 24, 2020.

XOMA Corporation reported its first quarter 2020 financial results and provided a COVID-19 business update.

Q1 GAAP diluted EPS from continuing operations of $0.91 versus prior-year GAAP diluted EPS from continuing operations of $0.78

Akebia Therapeutics, Inc., announced positive top-line results from INNO2VATE, its global Phase 3 cardiovascular outcomes program evaluating the efficacy and safety of vadadustat, its investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor, versus darbepoetin alfa for the treatment of anemia due to chronic kidney disease in adult patients on dialysis.

SightGlass Vision, Inc. announced it will hold an R&D webinar to discuss the science of and latest research in myopia, as well as provide an overview about the clinical development and commercialization program for the Company’s novel glasses designed to slow the progression of myopia in children.

Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced that Mel Sorensen, M.D., President and Chief Executive Officer, will virtually present at the BofA Securities 2020 Health Care Conference on Tuesday, May 12, 2020, at 9:40 a.m. EDT. A live audio webc

Baxter International Inc. announced an increase in the company’s quarterly cash dividend to a rate of $0.245 per share of common stock.